Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.

Autor: Louwsma J; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands., Brunger AF; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands., Bijzet J; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands., Kroesen BJ; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Laboratory medicine, University Medical Center Groningen, Groningen, The Netherlands., Roeloffzen WWH; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Bischof A; Department of Neurology, University Hospital Basel, Basel, Switzerland., Kuhle J; Department of Neurology, University Hospital Basel, Basel, Switzerland., Drost G; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands., Lange F; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands., Kuks JBM; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands., Gans ROB; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands., Hazenberg BPC; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.; Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands., Nienhuis HLA; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.; Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands.
Jazyk: angličtina
Zdroj: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2021 Mar; Vol. 28 (1), pp. 50-55. Date of Electronic Publication: 2020 Sep 04.
DOI: 10.1080/13506129.2020.1815696
Abstrakt: Objective: To study serum neurofilament light chain (sNfL) in amyloid light chain (AL) amyloidosis patients with and without polyneuropathy (PNP) and to corroborate previous observations that sNfL is increased in hereditary transthyretin-related (ATTRv) amyloidosis patients with PNP.
Methods: sNfL levels were assessed retrospectively in patients with AL amyloidosis with and without PNP (AL/PNP+ and AL/PNP-, respectively), patients with ATTRv amyloidosis and PNP (ATTRv/PNP+), asymptomatic transthyretin ( TTR) gene mutation carriers ( TTR v carriers) and healthy controls. Healthy controls (HC) were age- and sex-matched to both AL/PNP- (HC/AL) and TTR v carriers (HC/ TTR v). The single-molecule array (Simoa) assay was used to assess sNfL levels.
Results: sNfL levels were increased both in 10 AL/PNP+ patients ( p  < .001) and in 10 AL/PNP- patients ( p  < .005) compared to 10 HC/AL individuals. sNfL levels were higher in AL/PNP+ patients than in AL/PNP- patients ( p  < .005). sNfL levels were also increased in 15 ATTRv/PNP+ patients, compared to both 15 HC/ TTR v ( p  < .0001) and 15 TTR v carriers ( p  < .0001). ATTRv/PNP+ patients with progressive PNP (PND-score > I) had the highest sNfL levels compared to patients with early PNP (PND-score I) ( p  = .05). sNfL levels did not differ between TTR v carriers and HC/ TTR v individuals. In the group comprising all healthy controls and in the group of TTR v carriers, sNfL levels correlated with age.
Conclusion: sNfL levels are increased in patients with PNP in both AL and ATTRv amyloidosis and are related to severity of PNP in ATTRv amyloidosis. sNfL is a promising biomarker to detect PNP, not only in ATTRv but also in AL amyloidosis.
Databáze: MEDLINE
Externí odkaz: